2, 21.8 ± 3.3, 22.0 ± 3.3 (Prend = 0.079); eGFR (mL/min per 1.73 m2) 90 ± 15, 92 ± 16, and 90 ± 15 (Ptrend = 0.082); serum uric acid (mg/dL), 5.0 ± 1.4, 5.1 ± 1.4, and 5.3 ± 1.4. During median 2.9 yr selleck chemical (1.5–4.2) of the observational period, 301 (8.4%),

272 (8.9%), and 144 (10.7%) participants developed proteinuria and their incidence rate per 1000 person-year were 28.3 (95% confidence interval 25.2–31.7), 31.2 (27.6–35.2), and 37.4 (31.6–44.1), respectively (Ptrend = 0.007) (Figure). A multivariate-adjusted Poisson model identified ≥2 drinks/day as a significant predictor of proteinuria (vs. 0 drink/day; 1 drink/day, incidence rate ratio 1.03 (95% confidence interval 0.88–1.22), P = 0.698; 2 drinks/day, 1.28 (1.05–1.56), P < 0.015). Conclusion: Excessive soft drink consumption (≥2 drinks/day) predicts the incidence of proteinuria. KUMA AKIHIRO, TAMURA MASAHITO, HARUKI NOBUHIKO, MIYAMOTO TETSU, SERINO RYOTA, TAKEUCHI MASAAKI, OTSUJI YUTAKA The Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Introduction: It is particularly difficult to treat heart failure (HF) accompanied by chronic kidney disease (CKD). A recent study reported that CKD patients were also more likely to have

sleep apnea syndrome (SAS). Adaptive servo ventilation (ASV) has been indicated that it is effective Selleck Cabozantinib for treating and managing HF with SAS. So here we investigated whether ASV has benefits for cardiac and renal functions. Methods: This single-center retrospective study was conducted enough with non-replacement CKD patients. We selected a subgroup with drug-refractory

HF and SAS. ASV group patients received ASV (>4 hr/day) for 6 months and control group patients were received medication against for HF, but not ASV therapy. Changes in cardiac and renal function were assessed using the Wilcoxon signed-rank test and correlations by Spearman’s rank correlation. Results: ASV group (n = 23) comprised 16 males (mean age, 66.8 ± 12.2 years) and control group (n = 14) comprised 11 males (mean age, 69.1 ± 14.6 years). Estimated glomerular filtration rate (eGFR; median) of ASV group was 41.8 ml/min per 1.73 m2 before ASV therapy (0 M), 51.5 ml/min per 1.73 m2 1 month after ASV therapy (1 M) (p = 0.0071 vs 0 M), and improved eGFR was maintained for 6 months (6 M; 48.4 ml/min per 1.73 m2) (p = 0.5545 vs 1 M). However eGFR of control group was 49.40 (0 M), 49.45 (1 M) (p = 0.4703 vs 0 M), and tended to decrease for 6 months (6 M; 42.45) (p = 0.0596 vs 0 M). Left ventricular ejection fraction (LVEF; median) of ASV group was 29.1% (0 M), 38.2% (1 M) (p = 0.0019 vs 0 M), and no further change at 6 M (38.5%; p = 0.2166 vs 1 M). LVEF of control group was 40.0% (0 M), 37.6% (1 M) (p = 0.8993 vs 0 M), and no change at 6 M (34.5%; p = 0.7741 vs 1 M). In ASV group, no correlation was observed between baseline eGFR and the improvement in LVEF (0–6 M) (ρ = 0.1610, p = 0.4856).